Moderna COVID-19 vaccine approved in adolescents

The Moderna COVID-19 vaccine, now known as Spikevax, has been approved by the MHRA for use in children aged 12 to 17 years.

Spikevax is now indicated for COVID-19 vaccination from 12 years of age. | GETTY IMAGES
Spikevax is now indicated for COVID-19 vaccination from 12 years of age. | GETTY IMAGES

Spikevax has been authorised by the MHRA as 'safe and effective' for use in 12–17-year olds.

Further information

View COVID-19 vaccines

'It is for the Joint Committee on Vaccination and Immunisation (JCVI) to advise on whether this age group should be vaccinated with the COVID-19 vaccine made by Moderna as part of the deployment programme,' said MHRA chief executive Dr June Raine.

No new side-effects of the mRNA vaccine were identified in children  12–17 years and the safety data in this age group was comparable with that seen in young adults. As in young adults, the majority of adverse events were mild to moderate and relating to reactogenicity, such as a sore arm or tiredness.

Dr Raine said: 'We have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved COVID-19 vaccines and this surveillance will include the 12- to 17-year age group.'

The Pfizer/BioNTech COVID-19 mRNA vaccine Comirnaty is also approved for use from 12 years. Suitable age groups and other key characteristics of COVID-19 vaccines are summarised in the quick-reference MIMS comparison table.

Want news like this straight to your inbox?
Sign up for our bulletins

Chloe Harman recommends

Table: COVID-19 Vaccines

Read more

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in